Skip to content
Screener

Cytek Biosciences, Inc. CTKB China — Total revenue, net

Other geography segments

United States
$23.9M

Similar metrics at other companies

Viavi Solutions Inc. logo
VIAVCHINA — Total net revenue
$64.2M+23.7%
Synopsys logo
SNPSChina — Total Revenue
$240.4M+52.6%
Blaize Holdings logo
BZAIChina — Total Revenue
$0-100%
Arteris, Inc. logo
AIPChina — Total Revenue
$4.32M+2.3%
Azenta logo
AZTAChina — Total Revenue
$18.79M+31.2%
XPEL, Inc. logo
XPELChina — Total Revenue
$15.92M+107%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$545.93M+25.6%
Enterprise value$489.11M+29.2%
P/S2.6×+0.4×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496

$42.4 million for the three and six months ended June 30, 2025, respectively. Revenue in China was approximately $4.8 million and $8.4 million for the three and six months ended June 30, 2026, respectively. No other country represented greater than 10% of the Company’s consolidated net sales or was otherwise deemed significant. For the three and six months ended June 30, 2026 and 2025, the Company had no major customers that represented more than 10% of the Company’s total revenue. No customer represented more than 10% of net accounts receivable as of June 30, 2026 and 2025.

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s china — total revenue, net?
Cytek Biosciences, Inc. (CTKB) reported china — total revenue, net of $4.8M in Q2 2026.
How has Cytek Biosciences, Inc.'s china — total revenue, net changed year-over-year?
Cytek Biosciences, Inc.'s china — total revenue, net increased by 33.3% year-over-year, from $3.6M to $4.8M.
What does china — total revenue, net mean?
This metric represents the total net revenue generated from sales of instruments, reagents, and services within the China geographic market. It serves as a key indicator of the company's market penetration and adoption rates for its full-spectrum flow cytometry technology in this specific region. Monitoring this figure helps investors assess the company's international growth strategy and its competitive positioning within the rapidly expanding Chinese life sciences sector.

Ask your AI about Cytek Biosciences, Inc.'s china — total revenue, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude